

SFB824 Project C7 Publications

1. Krabbe T, Marek J, Groll T, Steiger K, Schmid RM, Krackhardt AM, Altomonte J. (2021) Adoptive T cell therapy is complemented by oncolytic virotherapy with fusogenic VSV-NDV in combination treatment of murine melanoma. *Cancers*, 13(5):1044.
2. Bliemsrieder E, Kaissis G, Grashei M, Topping G, Altomonte J, Hundshammer C, Lohöfer F, Heid I, Keim D, Gebrekidan S, Trajkovic-Arsic M, Winkelkotte A, Steiger K, Nawroth R, Siveke J, Schwaiger M, Makowski M, Schilling F, Braren R. (2021) Hyperpolarized ¹³C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC. *Sci Rep*, Jan 13;11(1).
3. Melzer MK, Zeitlinger L, Mall S, Steiger K, Schmid RM, Ebert O, Krackhardt A, and Altomonte J. (2018) Enhanced safety and efficacy of oncolytic VSV therapy by combination with T cell receptor transgenic T cells as carriers. *Mol Ther Oncolytics*, 12:26-40.
4. Abdullahi S, Jäkel M, Behrend SJ, Steiger K, Topping G, Krabbe T, Colombo A, Sandig V, Schiergens TS, Thasler WE, Werner J, Lichtenthaler SF, Schmid RM, Ebert O, and Altomonte J. (2018) A novel chimeric oncolytic virus vector for improved safety and efficacy in hepatocellular carcinoma. *J Virol*, 92(23).
5. Krabbe T and Altomonte J. (2018) Fusogenic viruses in oncolytic immunotherapy. *Cancers*, 10(7).
6. Melzer MK, Lopez-Martinez A, Altomonte J. (2017) Oncolytic vesicular stomatitis virus as a viro-immunotherapy: defeating cancer with a “hammer” and “anvil”. *Biomedicines* 5(1), 8.
7. Altomonte J, Muñoz-Alvarez K, Shinozaki K, Baumgartner C, Kaissis G, Braren R, and Ebert O. (2016) Transarterial administration of oncolytic viruses for locoregional therapy of orthotopic HCC in rats. *JoVE* (110).
8. Groß C, Steiger K, Sayyed S, Heid I, Feuchtinger A, Walch A, Heß J, Unger K, Zitzelsberger HF, Settles M, Schlitter AM, Dworniczak J, Altomonte J, Ebert O, Schwaiger M, Rummeny EJ, Steingötter A, Esposito I, Braren R. (2015) Model matters: differences in orthotopic rat hepatocellular carcinoma physiology determine therapy response to sorafenib. *Clin Cancer Res*, 21(19):4440-50.
9. Marozin S, Altomonte J, Muñoz-Álvarez KA, De Toni EN, Thasler WE, Schmid RM, Ebert O. (2015) STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma. *Cancer Gene Ther*, 22(6):317-25.
10. Almstätter I, Mykhaylyk O, Settles M, Altomonte J, Aichler M, Walch A, Rummeny EJ, Ebert O, Plank C, Braren R. (2015) Characterization of magnetic viral complexes for targeted delivery in oncology. *Theranostics*, 5(7):667-85.
11. Muñoz-Álvarez KA, Altomonte J, Laitinen I, Ziegler S, Steiger K, Esposito I, Schmid RM, Ebert O. (2015) PET imaging of oncolytic VSV expressing the mutant HSV-1 thymidine kinase transgene in a preclinical HCC rat model. *Mol Ther*, 23(4):728-36.
12. Altomonte J and Ebert O. (2014) Sorting out Pandora’s box: discerning the dynamic roles of liver microenvironment in oncolytic virus therapy for hepatocellular carcinoma. *Frontiers in Immunol*, 4:85.

13. Altomonte J, Marozin S, DeToni EN, Rizzani A, Esposito I, Steiger K, Feuchtinger A, Hellerbrand C, Schmid RM, Ebert O. (2013) Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis. *Mol Ther*, 21(11):2032-42.
14. Marozin, S., Altomonte, J., Apfel, S., Dinh, PX., De Toni, EN., Rizzani, A., Nüssler, A., Kato, N., Schmid, RM., Pattnaik, AK., Ebert, O. (2012) Posttranslational modification of vesicular stomatitis virus glycoprotein, but not JNK inhibition, is the antiviral mechanism of SP600125. *J Virol*, 86(9):4844-55.
15. Braren, R., Curcic, J., Remmele, S., Altomonte, J., Ebert, O., Rummeny, EJ., Steingoetter, A. (2011) Free-Breathing quantitative dynamic contrast-enhanced magnetic resonance imaging in a rat liver tumor model using dynamic radial T(1) mapping. *Invest Radiol*, 46(10):624-31.
16. Braren, R., Altomonte, J., Settles, M, Neff F, Esposito I, Ebert O, Schwaiger M, Rummeny E, Steingoetter A. (2011) Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization. *Journal of Hepatology*, 55(5):1034-40.
17. Marozin, S., De Toni, EN., Rizzani, A., Altomonte, J., Junger, A., Schneider, G., Thasler, WE., Kato, N., Schmid, RM., Ebert, O. (2010) Cell cycle progression or translational control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma. *PLoS One*, 5(6):e10988.